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Abstract – The advanced knowledge about genetic 
diseases and their mutations has widened the possibility to 
have a more precise and definitive diagnosis in many 
patients, but the use of genetic testing is still controversial. 
Actually, many cardiomyopathies show the availability of 
genetic testing. The clinical utility of this testing has been 
widely debated, but it is evident that the use of genetics 
must be put in a more organic diagnostic pathway that 
includes the evaluation of risks and benefits for the patient 
and his relatives, as well as the costs of the procedure. 
This review aims to clarify the role of genetic in clinics 
regarding Channelopaties, less frequent but equally 
important than other Cardiomyopathies because patients 
can often be asymptomatic until the first fatal 
manifestation. 
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I.  INTRODUCTION 
 
 The aims of this review are to understand the 
indication for the execution of genetic tests in patients 
with Channelopaties and appreciate the difficulties of the 
interpretation of these tests in the clinical practice. The 
Channelopaties are less frequent than other 
cardiomyopathies. The patient is often asymptomatic, 
even if the first clinical manifestation can be fatal. Among 
the Channelopaties,  the most relevant are the Long QT 
Syndrome,  (LQTS), the Short QT Syndrome (SQTS), the 
Brugada Syndrome (BrS) and the Catecholaminergic 
Polymorphic Ventricular Tachycardia (CPVT). 
Different Channelopaties with different prognosis 
could derive from different mutations involving the same 
gene. Mutations of SCN5a gene can cause the Brugada 
Syndrome and the LQTS. However, the interpretation of 
the genetic tests is difficult because they are probabilistic 
and not deterministic tests. Furthermore, a test could be 
positive for the presence of a DNA variant with an 
uncertain clinical significance.  
 
 
II. THE CONGENITAL LONG QT SYNDROME 
 
Congenital long QT syndrome (LQTS) is a 
genetic condition characterized by a prolonged QT 
interval registered by an ECG and associated with the 
history of syncope and ventricular tachyarrhythmias, the 
evidence of T-wave abnormalities, and the high risk of a 
sudden cardiac death [1]. The QTc-interval prolongation 
reflects the prolonged cardiac repolarization. The QT can 
also be increased by the administration of drugs as 
antidepressants and antiarrhythmics, or in electrolyte 
disturbances and structural heart diseases. According to 
diagnostic criteria proposed by Schwartz et al, the 
diagnosis is based on clinics [2]. These criteria (table 1) 
do not consider the results of genetic testing, even if these 
tests are extremely crucial to recognize familiar and 
asymptomatic carriers. Among symptomatic index cases, 
the untreated 10-year mortality is approximately 50% [3-
5]. The QT interval is not the right mean to evidence  
LQTS because it shortens when the heart rate increases. 
Thus, it is necessary to use a rate-corrected QT interval to 
value QT, usually Bazett’s formula is used (QTc= QT/RR 
1/2). 
There are four clinical types of defined congenital 
LQTS (cLQTS), including: 
 Romano-Ward Syndrome,  with autosomal 
dominant inheritance and  prevalence of 1:2,500 
(LQTS is present alone) [6];  
 Jervell-Lange Nielsen Syndrome, with autosomal 
recessive inheritance associated with congenital 
deafness and a rare syndrome; 
 Andersen Syndrome, the LQTS is variably 
presented together with arrhythmias, periodic 
paralysis, and malformations; 
 Timothy Syndrome, an extremely rare disease, 
characterized by severe LQTS, cardiac and other 
somatic malformations, and autism.  
The acquired syndrome is more frequent than the 
congenital LQTS, so it is necessary to diagnose LQTS and 
exclude secondary syndrome. 
 The genetic test for LQTS. Congenital LQTS 
(Romano-Ward Syndrome) is an autosomal dominant 
monogenic disorder with variable penetrance. About 85% 
of the reported cases is inherited parentally while the 
remaining 15% of patients has a de novo mutation. 
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Actually, mutations have been identified in 13 different 
genes, although mutations of LQT1, LQT2, and LQT3 are 
evidenced in the 95% of the cases.  




A. QTcb  
- ≥480 ms1/2 3 
- 460–470 ms1/2 2 
- 450 (males) 1 
B. Torsades de pointesc 2 
C. T-wave alternans 1 
D. Notched T-wave in three leads 1 
E. Low heart rate for aged 0.5 
Clinical history  
A. Syncopec 
- with stress 
- without stress 








A. Family members with LQTSf 1 
B. SD among immediate family 
members below 30 years 
0.5 
 
Table 1. Diagnostic criteria for LQTS. 
a In the absence of medications or disorders known to affect 
these electrocardiographic features. 
b QTc calculated by Bazett’s formula, where QTc = QT/ 
√RR 
c Mutually exclusive. 
d Resting heart rate below the second percentile for age 
[Davignon et al., 1980]. 
e The same family member can not be counted in A and B. 
Low probability of LQTS is defined by an LQTS score r1 point; 
an intermediate probability of LQTS is defined by an LQTS 
score of 2 to 3 points; Z4 points, high probability of LQTS. 
Modified from Schwartz et al. [1993]. 




These mutations alter the function of specific ion 
channels during the normal depolarization, evidenced by a 
prolongation of the QT interval on the surface ECG.   
As shown in table 2, about 70% of all the LQTS is 
caused by loss-of-function mutations of the Kv7.1(Iks) 
potassium channel (LQT1) or the Kv11.1 (IKr) potassium 
channel (LQT2) while  5%-10% is caused by gain-of-
function mutations of the Nav1.5 (INa) sodium channel 
(LQT3). The LQT8 derived by gain-of-function mutations 
in the CACNA1C encoding for an L-type calcium channel 
subunit. The use of the genetic analysis of KCNQ1, 
KCNH2, and SCN5A must be considered in patients with 
a LQTS phenotype. However, the analysis of all LQTS 
genes has not a good evidence and has to be reserved to 
cases where the clinical suspicion is high, and the 
previous analysis is negative [7-8]. 
Clinical LQTS genetic testing is recommended for 
any index case when a clinical cardiologist suggests the 
presence of a LQTS, considering the patient’s history of 
syncope, the familiar history, the QT interval duration, 
and the response to catecholamine stress testing. LQTS 
genetic testing is recommended for asymptomatic patients 
with QT prolongation (QTc≥500 ms in adults); in patients 
where the QT prolongation cannot be attributed to 
secondary conditions associated QT prolongation (e.g. 
electrolyte, cardiac hypertrophy, bundle branch block, 
diabetes). LQTS genetic testing may be considered for 
serial QTc values, on 12-lead ECG≥480 ms in adults, 
while is not recommended in patients with drug induced 
LQTS. Furthermore, it must not be performed as part of 
pre-sports participation or as part of a universal screening 
protocol. [9] 
A normal QTc on the surface ECG does not exclude 
the presence of LQTs in relatives and so a genetic-test 
must be performed in relatives of an index case. After the 
discovery of a causative mutation, family screening is 
indicated in all first-degree relatives. Prognostically, the 
LQT3 mutations are associated with a higher mortality 
than LQT1 e LQT2 mutations. 
Therapeutically, the use of beta blockers is more 
protective in LQT1 patients, whether in patient with LQT3 
it is less protective. The treatment of these patients must 
consider the use of drugs interacting with sodium current 
as Flecainide or Mexiletine. The implant of ICD must be 
performed according the traditional criteria [10-13]. 
 
 
III. THE SHORT QT SYNDROME 
 
In 2000 Gussak et al described a new syndrome 
characterized by a short QT interval shown by a surface 
ECG, the evidence of malignant ventricular arrhythmias 
and atrial fibrillation, and the increased risk of sudden 
death in young people even in the absence of a structural 
cardiopathy [14]. This syndrome is rarer than LQTS, 
whether the real prevalence is unknown. Epidemiological 
data from Finnish population showed that 97.5% of males 
had a QTc longer than 348 ms while the value identified 
for females was 364 ms [15].  In 2011 Gollob et all 
defined the clinical criteria for the diagnosis of SQTS. The 
authors considered 61 patients and made a score using 
data from these patients (Table 3)[16]. There is not a 
widely accepted cut-off for QTc, but generally these 
patients present a QT interval shorter than 320 ms. The 
implantation of a defibrillator is the only possible therapy 
when there is a history of SCD or unexplained syncope. 
Asymptomatic patients can be treatment with Quinidine, 
but data are not certain [17]. 
The genetic test for SQTS. In contrast to LQTS, 
the role of genetic testing is limited in SQTS because 
currently several patients, who have a positive phenotype, 
have unknown genetic mutations. Three SQTS-
susceptibility potassium channel genes showed mutations 
involved in SQTS: KCNH2, KCNQ1, and KCNJ2. These 
are usually mutations with a gain-of-function, and 
repolarization is faster than normally. Obviously, this 
electrophysiological alteration is not evidenced in all 
ventricular cells, leading to the creation of a ventricular 
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electrical gradient and so a higher susceptibility to 
ventricular arrhythmia. This syndrome has an autosomal 
inheritance, and variable penetrance. After the 









LQTS 1 KCNQ1 
Alpha-subunit of the slow delayed rectifier 
potassium channel (Iks) 
The first cause of LQTS 
cardiac events during exercise 
LQTS 2 HERG 
Alpha-subunit of the rapid delayed rectifier 
potassium channel (Ikr) 
The second cause of LQTS 
cardiac events occurs during 
arousal 
LQTS 3 SCN5A Alpha-subunit of sodium channel 
Cardiac events during 
rest/bradycardia 
Rarely overlaps with Brugada 
syndrome 
LQTS 4 Ankyrin B 





LQTS 5 KCNE1 
MiRP1 beta-subunit of voltage-gated potassium 
channel 
Heterozygote mutation in 
Romano-Ward syndrome 
Homozygote mutation results in 
JLNS 
LQTS 6 KCNE2 




LQTS 7 KCNJ2 Inward-rectifier potassium channel Andersen-Tawil syndrome 
LQTS 8 CACNA1c Alpha-1c-subunit of the L-type calcium channel 
 
 
LQTS 9 Cav3 Caveolin 3 
 
 
LQTS 10 SCN4B Sodium channel 
 
 
LQTS 11 AKAP9 A-kinase anchor protein 9 
 
 
LQTS 12 SNTA1 Alpha-1-syntrophin 
 
 
LQTS 13 GIRK4 





Table 2. Currently identified LQTS gene mutations 
 
 
Parameters Characteristics Symptomatic Asymptomatic 
QT (ms) 
n 


































77.4 ±  6.6 
78 (74–80) 
64–93 
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Table 3.  Parameters in Symptomatic and Asymptomatic SQTS Cases.  SQTS: short QT syndrome; QTc: Bazett corrected QT 
interval; QTp:  predicted QT interval. 
mutation in the index case, genetic testing is 
recommended for first-degree relatives [1]. 
 
 
IV. CATECHOLAMINERGIC POLYMORPHIC 
VENTRICULAR TACHYCARDIA 
 
Although the diagnosis is usually performed 
when the patient is about twenty-thirty year old and the 
first symptom is syncope, one third of patients show 
symptoms in childhood. 
There are two types of CPVT: 
 an autosomal dominant type, caused by mutations 
of the gene encoding for  the Ryanodine receptor 
(RyR2), reported in the 60 % of the patients; 
 a rarer type, due to mutations of the gene for 
cardiac calsequestrin (CASQ2), reported  in less 
than 5% of the patients. 
Both show an increased re-uptake of Calcium by 
sarcoplasmic reticulum with a spontaneous release of 
Calcium causing delayed after depolarizations. Sometimes 
the ICD does not protect against Sudden Death because 
the after depolarizations can determine an significant 
arrhythmic storm. Drugs such as Beta-blocks and Ca-
Antagonist are useful just in a small number of patients 
[19,21].  
Genetic-test for CPVT. More than 100 RyR2 
mutations have been discovered for the dominant type of 
CPVT. They involve specific clusters/regions of the 
protein, such as FKBP12.6 binding domain, the trans-
membrane segments and C-terminus. These regions are 
extremely large, so some laboratories are not able to 
evaluate every cluster during a screening test. However, if 
the first screening is negative, the entire region must be 
analysed [20]. CASQ2 mutations are rare. Consequently, 
only 12 CPVT-associated mutations show to affect this 
gene. CASQ2 mutations may also cause an autosomal 
dominant transmission of the phenotype. It is necessary to 
screen CASQ2 in sporadic RYR2-negative index cases. 
[21] 
The patients with a non-typical clinical expression 
rarely have these mutations. So it is unclear if it is useful 
the screening in patients with IVF and not bi-directional 
ventricular tachycardia. 
Mutations of KCNJ2, encoding for the Kir2.1 
potassium channel, and of ANKB, encoding for ankyrin 
B, can show the presence of clinical symptoms similar to 
CPVT. However, it is not known the utility of the screen 
of these genes. The genetic testing for the index case's 
mutation is indicated in first-degree relatives, even if the 
phenotype is negative.   
 
V. BRUGADA SYNDROME 
 
The presence of an abnormal ECG with right 
bundle branch block pattern and coved-type ST elevation 
over the right precordial leads characterizes the Brugada 
syndrome (BS). This disease shows an increased risk of 
sudden cardiac death in patients with structurally normal 
hearts [22]. Patients with BS can be asymptomatic for 
many years. The first clinical presentation is often a 
sudden death [23]. Common symptoms are syncope and 
agonic breath during the night for the presence of self -
terminating ventricular fibrillation episodes [23,24].  
Worldwide, BS is estimated to be responsible for 
at least 20% of sudden deaths in patients with structurally 
normal hearts [23, 25]. The ECG guides the diagnosis, 
even if it can show diagnostic features intermittently. 
Three ECG patterns have been described: Type 1 pattern 
has a coved ST-segment elevation ≥2 mm, with a negative 
T-wave; Type 2 has a saddleback  ST-segment elevation 
≥2 mm,  and a positive or biphasic T wave; Type 3 has a 
coved or saddleback ST-segment elevation type <1 mm. 
The administration of sodium channel blockers and the 
placement of right precordial leads over the higher 
intercostal spaces significantly increases the diagnostic 
yield unmasking the ECG pattern of the disease [26-28]. 
Furthermore, ECG pattern can be modulated by a febrile 
state, autonomic nervous system changes, tricyclic or 
tetracyclic antidepressants, first-generation antihistamines, 
alcohol, and electrolytes abnormalities.  
The only therapy demonstrated to be successful in BS is 
ICD implantation. The Consensus on BS [23] stated that 
patients with a prior resuscitated sudden death and 
demonstrated episodes of self-terminating ventricular 
fibrillation, unexplained syncope, and agonic breath 
during the night have a Class I evidence for ICD 
implantation. Unfortunately, the risk stratification lacks in 
the identification of high risk asymptomatic patients [29-
31]. 
Genetic Test for BS. BS is inherited with an 
autosomal dominant pattern, but the prevalence is up to 
10-fold higher in males, who also exhibit a greater 
severity of the disease [32]. The first mutation linked to 
BS was identified in the SCN5A gene, which encodes for 
the α-subunit of the sodium channel [33]. In the last years, 
several gene mutations have been identified causing loss 
of-function of the sodium channel [34-36], producing 
decreased sodium current, which results in an impaired  
phase 0 of the action potential and thus producing an 
arrhythmic substrate. Recently, even mutations of 
potassium and calcium channels have been related to BS 
[37].  
Although many mutations have been identified 
and the genetic heterogeneity of this syndrome has been 
established,   the precise causal role of the mutation is not 
fully understood. Indeed, the presence of a mutation is not 
entirely responsible of the phenotype. Many carriers of 
mutations present a normal ECG pattern at baseline and 
after the infusion of a blocker sodium channel [38]. In 
addition, a case of identical twins with SCN5A mutations 
has been reported recently where only one twin displayed 
the BS phenotype [39]. These findings suggest that the 
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mutated SCN5A could act as a modifier of others mutated 
causal genes.  
Experts consensus of the Heart Rhythm 
Society/European Heart Rhythm Association [9] stated 
that extensive BS genetic testing can be useful in case of a 
clinical index of suspicion based on evaluation of the 
patient’s clinical history, family history, and expressed 
electrocardiographic phenotype. On the contrary, genetic 
testing is not recommended in the setting of an isolated 
type 2 or type 3 BS ECG pattern. Finally, the genetic 
family screening is recommended after the identification 
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